

Receipt date: 06/17/2011

OK TO ENTER: /SH/

06/20/2011

Docket No. PAT100-8024-US-DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Sedrani et al.

APPLICATION NO: 09/585,743

FILED: June 2, 2000

FOR: Rapamycin Assay

Art Unit: 1641

Examiner: HAQ, SHAFIQUL

Confirmation No. 7135

**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

AMENDMENT

Dear Sir:

By this paper, Applicants wish to amend the specification of the above referenced application as follows:

**Amendments to the specification** are given on page 2 of this paper; and  
**Remarks/Arguments** begin on page 3 of this paper.

**Amendments to the specification**

Please add the following new paragraph on page 13, line 5 (before Example 1)

**Brief Description of the Drawings**

Fig 1 is a line graph depicting titer curves for mouse (M1) and mouse (M7).

Fig. 2 is a line graph depicting a standard curve for monoclonal antibody M7-91.

Fig. 3 is a bar graph showing a comparison of binding levels of 17 selected monoclonal antibodies in the rapamycin-BSA and FK-506 assays.

Fig. 4 is a bar graph showing a comparison of cross reactivity of 17 selected monoclonal antibodies in the rapamycin-BSA and FK-506 assays.

Fig. 5 is a line graph showing an inhibition curve for binding of the M7-91 antibody (M7.91.13) to BSA-rapamycin in the presence of different concentrations of free rapamycin.

Fig. 6A-B are line graphs showing a competitive assay comparing the M7-91 antibody (M7.91.13) with M1-303 (M1.303.3) antibody.

Figs. 7A-C are bar graphs of hybridoma B3-203 binding selectively to 40-O-(2-hydroxyethyl)-rapamycin-B- SA (7A), of hybridoma B3-113 binding both 40-O-(2-hydroxyethyl)-rapamycin-BSA and rapamycin-BSA conjugated through position 28 (7B), of hybridoma B3-164 binding rapamycin coupled to BSA through position 40 (7C).

Figs. 8A-C are line graphs showing antibodies produced by hybridoma B3-203 react strongly with 40-O-(2-hydroxyethyl)-rapamycin with low crossreactivity for rapamycin (FIG. 8A) and antibodies produced by hybridoma B3-113 and B3-164 bind equally well to 40-O-(2-hydroxyethyl)-rapamycin and rapamycin (FIGS. 8B and 8C).

Receipt date: 06/17/2011

Application No. 09/585,743

Attorney Docket No. Case . PAT100-8024-US-DIV

**REMARKS**

Applicants would like to thank Examiner Haq for discussing the present case with Applicants on June 15, 2011. Applicants have amended the specification to include a "Brief Description of the Drawings". Support for this amendment can be found on page 18, lines 19-23 and page 20, line 1 through page 21, line 26.

Applicants also submit herewith a new supplemental IDS, which consideration is kindly requested.

**CONCLUSION**

The Commissioner is authorized to charge Deposit Account No. 19-0134 for the \$180.00 fee for submitting the IDS. Applicants believe that no other fees are due. However, if any fees are required, the Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis for any fees due.

Respectfully submitted,

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936

/Christine McCormack/

Date: June 17, 2011

Christine McCormack  
Attorney for Applicant  
Reg. No. 61,331  
(617) 871-8486